Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Resources>Application Notes>This Application Note
  Application Notes
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Biomarker for Parkinson's Disease Found in Urine Samples
Protein identified as Parkinson's biomarker sourced from patient's stored frozen urine samples.
Testing for Malaria or Cancer at Home
Chemist develops tech to save lives in rural Africa.
Scroll Up
Scroll Down

The Nucleofector® 96-well Shuttle® System – Nucleofection® of Cell Lines and Primary Cells in an Automated Framework
Bookmark and Share

Amaxa GMBH

Screening of siRNA or cDNA libraries requires an automated high-throughput transfection process. Besides mere throughput considerations, the main drivers for automation are the standardization and robustness of the process. Stability of all cell parameters is the key to statistically relevant data and valid results. Therefore we analyzed the stability of transfection results of different cell types during a time span typically needed to screen a focused siRNA library using Nucleofection®. The transfection results generated demonstrate the robustness of the automated Nucleofection® process.

Further Information

Related Content

amaxa to Co-ordinate Collaboration to Develop High Throughput Devices for Primary Cell Transfection
amaxa receives a €2.75M grant from European Commission to develop devices for use in the study of immunological, neuronal and liver disorders.
Monday, July 02, 2007
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!